We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Teva Announces FDA Acceptance of NDA for SD-809 for Huntington Disease Treatment

News   Aug 17, 2015

 
Teva Announces FDA Acceptance of NDA for SD-809 for Huntington Disease Treatment
 
 
 

RELATED ARTICLES

Colorectal Cancer Vaccine Proves Safe in Phase I Trial

News

A new colorectal cancer vaccine showed positive results in the phase 1 clinical trial to demonstrate that the approach is safe. The patients treated had no signs of serious adverse events and samples of their blood contained markers of immune activation – an early indication that the vaccine could activate immune cells to fight colorectal tumors and metastases.

READ MORE

Drugs to Prevent Stroke and Dementia Show Promise in Early Trial

News

Treatments that prevent recurrence of types of stroke and dementia caused by damage to small blood vessels in the brain have moved a step closer, following a small study.

READ MORE

Targeted Therapy Proves Effective Against Aggressive Blood Cancer in Clinical Trial

News

A multi-institutional clinical trial has given good results for a targeted therapy to treat a rare, aggressive blood cancer known as blastic plasmacytoid dendritic-cell neoplasm (BPDCN).

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE